Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofazimine added to background regimen for multidrug-resistant pulmonary tuberculosis
2015-004440-19Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of clofazimine in pulmonary tuberculosis (TB) and multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Novartis. Started Dec 2015; status: terminated.
02
Drugs
clofazimine
03
Conditions
pulmonary tuberculosis (TB)multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on 2015-004440-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004440-19.